Antiviral Agents from Plants and Herbs: A Systematic Review
Abstract
Background and aims
Many antiviral compounds presently in clinical use have a narrow spectrum of activity, limited therapeutic usefulness and variable toxicity. There is also an emerging problem of resistant viral strains. This study was undertaken to examine the published literature on herbs and plants with antiviral activity, their laboratory evaluation in vitro and in vivo, and evidence of human clinical efficacy.
Methods
Independent literature searches were performed on MEDLINE, EMBASE, CISCOM, AMED and Cochrane Library for information on plants and herbs with antiviral activity. There was no restriction on the language of publication. Data from clinical trials of single herb preparations used to treat uncomplicated viral infections were extracted in a standardized, predefined manner.
Results
Many hundreds of herbal preparations with antiviral activity were identified and the results of one search presented as an example. Yet extracts from only 11 species met the inclusion criteria of this review and have been tested in clinical trials. They have been used in a total of 33 randomized, and a further eight non-randomized, clinical trials. Fourteen of these trials described the use of Phyllanthus spp. for treatment of hepatitis B, seven reporting positive and seven reporting negative results. The other 10 herbal medicines had each been tested in between one and nine clinical trials. Only four of these 26 trials reported no benefit from the herbal product.
Conclusions
Though most of the clinical trials located reported some benefits from use of antiviral herbal medicines, negative trials may not be published at all. There remains a need for larger, stringently designed, randomized clinical trials to provide conclusive evidence of their efficacy.
References
1. Jadad J.R., Moore A., Carroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., & McQuay H.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996; 17: 1–12.
2. Koytchev R., Alken R.G., & Dundarov S. Balm mint extract (Lo-701) for topical treatment of recurring Herpes labialis. Phytomedicine 1999; 6: 225–230.
3. Unander D.W., Webster G.L., & Blumberg B.S. Usage and bioassays in Phyllanthus (Euphorbiaceae). I V. Clustering of antiviral uses and other effects. Journal of Ethnopharmacology 1995; 45: 1–18.
4. Liu J., Lin H., & McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. Journal of Viral Hepatitis 2001; 8: 358–366.
5. Calixto J.B., Santos A.R.S., Filbo V.C., & Yunes R.A. A review of the plants of the genus Phyllanthus: their chemistry, pharmacology and therapeutic potential. Medical Research Review 1998; 18: 225–258.
6. Lee C.D., Ott M., Thyagarajan S.P., Shafritz D.A., Burk R.D., & Gupta S. Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication. European Journal of Clinical Investigation 1996; 26: 1069–1076.
7. Blumberg B.S., Millman I., Venkateswaran P.S., & Thyagarajan S.P. Hepatitis B and primary hepatocellular carcinoma: treatment of HBV carriers with Phyllanthus amarus. Vaccine 1990; 8: S86–S92.
8. Thyagarajan S.P., Subramanian S., Thirunalasundari T., Venkateswaran P.S., & Blumberg B.S. Effect of Phyllanthus amarus on chronic carriers of Hepatitis B virus. Lancet 1988; 2: 764–766.
9. Thyagarajan S.P., Jayaram S., Valliammai T., Madanagopalan N., Pal V.G., & Jayaraman K. Phyllanthus amarus and hepatitis B. Lancet 1990; 336: 949–950.
10. Leelarasamee A., Trakulsomboon S., Maunwongyathi P., Somanabandhu A., Pidetcha P., Matrakool B., Lebnak T., Ridthimat W., & Chandanayingyong D. Failure of Phyllanthus amarus to eradicate hepatitis B surface antigen from symptomless carriers. Lancet 1990; 335: 1600–1601.
11. Thamlikitkul V., Wasuwat S., & Kanchanapee P. Efficacy of Phyllanthus amarus for eradication of hepatitis B virus in chronic carriers. Journal of the Medical Association of Thailand 1991; 74: 381–385.
12. Berk L., deMan R.A., Schalm S.W., Labadie R.P., & Heitjtink R.A. Beneficial effects of Phyllanthus amarus for chronic hepatitis B, not confirmed. Journal of Hepatology 1991; 12: 405–406.
13. Milne A., Hopkirk N., Lucas C.R., Waldon J., & Foo Y. Failure of New Zealand hepatitis B carriers to respond to Phyllanthus amarus. New Zealand Medical Journal 1994; 107: 253.
14. Wang M., Cheng H., Li Y., Meng L., Zhao G., & Mai K. Herbs of the genus Phyllanthus in the treatment of chronic hepatitis B: observations with three preparations from different geographic sites. Journal of Laboratory & Clinical Medicine 1995; 350–352.
15. Peng X.C., Liu X.L., Liu S.C., Yang D.Z., Wang W.J., & Zhang H.J. [Preliminary observation of therapeutic effect of Phyllanthus herb on chronic HBsAg carriers]. Chinese Journal of Experimental Clinical Virology 1993; 7: 306–307.
16. Cao W.Z., Liu J.Q., Cao D.Y., Su F., & Xu S.G. [Clinical study on anti-HBV activity of Phyllanthus herb from Anhui, China]. China Journal of Chinese Materia Medica 1998; 23: 180–181.
17. Zhang J.L., He W.N., & Ye P. [Clinical observations on Phyllanthus amarus for treating chronic hepatitis HBV infection]. Chinese Journal of Integrated Traditional & Western Medicine on Liver Dieases 1992; 2: 8–10.
18. Huang K.M. [Genus Phyllanthus for treatment of 38 cases of chronic hepatitis B]. Information on Traditional Chinese Medicine 1999; 6: 32.
19. Huang Z.R., Zhong J.P., Zhu G.L., Chen Y.R., & Wang G.Q. [Therapeutic observations on Phyllanthus amarus for hepatitis B]. Chinese Journal of Clinical Hepatology 1993; 9: 108–110.
20. Zhu F.M., Zhang J.Q., Zhang X.Z., & Zhang X.M. [Observation on the effect of Fujian's Phyllanthus amarus treatment of HBV infection]. Chinese Journal of Integrated Traditional & Western Medicine on Liver Disease 1992; 2: 10–11.
21. Narendranathan M., Remla A., Mini P.C., & Satheesh P. A trial of Phyllanthus amarus in acute viral hepatitis. Tropical Gastroenterology 1999; 20: 164–166.
22. Boon H., & Smith M. The Botanical Pharmacy. 1999; Quarry Press Inc. Kingston, On., Canada.
23. Wobling R.H., & Leonhardt K. Local therapy of herpes simplex with dried extract from Melissa officinalis. Phytomedicine 1994; 1: 25–31.
24. Zakay-Rones Z., Varsano N., Zlotnik M., Manor O., Regev L., Schlesinger M., & Mumcuoglu M. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nigra L) during an outbreak of influenza B Panama. Journal of Alternative & Complementary Medicine 1995; 1: 361–369.
25. Thom E., Zakay-Rones Z., Wollan T., & Wadstein J. Randomised study on the efficacy and safety of an oral elderberry extract in the treatment of influenza A and B virus infections. Proceedings of the 15th International Conference on Antiviral Research. Prague, Czech Republic, March 2002.
26. Madav S., Tandan S.K., Lal J., & Tripathi H.C. Anti-inflammatory activity of andrographolide. Fitotherapia 1996; LXVII: 452–458.
27. Puri A., Saxena R., Saxena R.P., Saxena K.C., Srivastava V., & Tandonj J.S. Immunostimulant agents from Andrographis paniculata. Journal of Natural Products 1993; 56: 995–999.
28. Chang R.S., Ding L., Chen G.Q., Pan Q.C., Zhao Z.L., & Smith K.M. Dehydroandrographolide succinic acid monoester as an inhibitor against the human immunodeficiency virus. Proceedings of the Society of Experimental & Biological Medicine 1991; 197: 59–66.
29. Caceres D.D., Hancke J.L., Burgos R.A., & Wikman G.K. Prevention of common colds with Andrographis paniculata dried extract. A pilot double blind trial. Phytomedicine 1997; 4: 101–104.
30. Hancke J., Burgos R., Caceres D., & Wikman G. A double-blind study with a new monodrug kan jang: decrease of symptoms and improvement in the recovery from common colds. Phytotherapy Research 1995; 9: 559–562.
31. Caceres D.D., Hancke J.L., Burgos R.A., Sandberg F., & Wikman G.K. Use of visual analogue scale measurements (VAS) to assess the effectiveness of standardized Andrographis paniculata extract SHA-10 in reducing the symptoms of common cold. A randomized double blind placebo study. Phytomedicine 1999; 6: 217–223.
32. Melchoir J., Palm S., & Wikman G. Controlled clinical study of standardised Andrographis paniculata extract in common cold – a pilot trial. Phytomedicine 1996; 3: 315–318.
33. Calabrese C., Berman S.H., Babish J.G., Ma X., Shinto L., Dorr M., Wells K., Wenner C.A., & Standish L.J. A Phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytotherapy Research 2000; 14: 333–338.
34. Yoosook C., Panpisutchai Y., Chaichana S., Santisuk T., & Reutrakul V. Evaluation of anti-HSV-2 activities of Barleria lupulina and Clinacanthus nutans. Journal of Ethnopharmacology 1999; 67: 179–187.
35. Sangkitporn S., Chaiwat S., Balachandra K., Na-Ayudhaya T.D., Bunjob M., & Jayavasu C. Treatment of herpes zoster with Clinacanthus nutans (bi phaya yaw) extract. Journal of the Medical Association of Thailand 1995; 178: 624–627.
36. Jayavasu C., Balachandra K., Sangkitporn S., Maharungraungrat A., Thavatsupa P., Bunjob M., Chavalittumrong P., Dechatiwongse Na Ayudhaya T., & Sittisomwong N. Clinical trial in the treatment of genital herpes patients with Clinacanthus nutans extract. Communicable Disease Journal 1992; 18: 152–161.
37. Charuwichitratana S., Wongrattanapasson N., Timpatanapong P., & Bunjob M. Herpes zoster: treatment with Clinacanthus nutans cream. International Journal of Dermatology 1996; 35: 665–666.
38. Vogler B.K., & Ernst E. Aloe vera: a systemic review of its clinical effectiveness. British Journal of General Practice. 1999; 49: 823–828.
39. Syed T.A., Cheema K.M., Ashfaq Ahmad S., & Holt A.H. Jr. Aloe vera extract 0.5% in hydrophilic cream versus Aloe vera gel for the management of genital herpes in males. A placebo-controlled, double-blind comparative study. Journal of the European Academy of Dermatology & Venerology 1996; 7: 294–295.
40. Syed T.A., Afzal M., Ashfaq Ahmad S., Holt A.H., Ali Ahmad S., & Ahmad S.H. Management of genital herpes in men with 0.5% Aloe vera extract in hydrophilic cream: a placebo-controlled double-blind study. Journal of Dermatological Treatment 1997; 8: 99–102.
41. Schnitzler P., Schon K., & Reichling J. Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture. Pharmazie 2001; 56: 343–347.
42. Carson C.F., Ashton L., Dry L., Smith D.W., & Riley T.V. Melaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis. Journal of Antimicrobial Chemotherapy 2001; 48: 450–451.
43. Durant J., Chantre G., Gonzalez G., Vandermander J., Halfon Ph, Rousse B., Guedon D., Rahelinirina V., Chamaret S., Montagnier L., & Dellamonica P. Efficacy and safety of Buxus sempervirens L preparations (SPV30) in HIV-infected patients: a multicentre, randomized, double-blind, placebo-controlled trial. Phytomedicine 1998; 5: 1–10.
44. Ankri S., & Mirelman D. Antimicrobial properties of allicin from garlic. Microbes & Infection 1999; 1: 125–129.
45. Weber N.D., Andersen D.O., North J.A., Murray B.K., Lawson L.D., & Hughes B.G. In vitro virucidal effects of Allium sativum (garlic) extract and compounds. Planta Medica 1992; 58: 417–423.
46. Josling P. Preventing the common cold with a garlic supplement: a double-blind, placebo-controlled survey. Advances in Therapy 2001; 18: 189–193.
47. Newall C.A., Anderson L.A., & Phillipson J.D. Herbal Medicines, A Guide for Healthcare Professionals. 1996; London: Pharmaceutical Press.
48. Thom E., & Wollan T. A controlled clinical study of Kanjang mixture in the treatment of uncomplicated upper respiratory tract infections. Phytotherapy Research 1997; II: 207–210.
49. Saller R., Buechi S., Meyrat R., & Schmidhauser C. Combined herbal preparation for topical treatment of herpes labialis. Forsch Komplementarmed Klass Naturheilkd 2001; 8: 373–382.
50. Shibata S. A drug over the millennia: pharmacognosy, chemistry and pharmacology of licorice. Yakugaku Zasshi 2000; 120: 849–862.
51. Pompei R., Flore O., Marccialis M.A., & Pani A., & Loddo B. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 1979; 25: 689–690.
52. Crance J.M., Leveque F., Biziagos E., van Cuyck-Gandre H., Jouan A., & Deloince R. Studies on the mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Research 1994; 23: 63–76.
53. Su X., Chen H., Wang L., Jiang C., Liu J., Zhao M., Ma X., Zhao Y., & Han D. Clinical and laboratory observation on the effect of glycyrrhizin in acute and chronic hepatitis. Journal of Traditional Chinese Medicine 1984; 4: 127–132.
54. Suzuki H., Ohta Y., Tekino T., Fujisawa K., & Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Asian Medical Journal 1983; 26: 423–438.
55. Arase Y., Ikeda K., Murashima N., Chayama K., Tsubota A., Koida I., Susuki Y., Saitoh S., Kobayashi M., & Kumada H. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494–1500.
56. Tsubota A., Kumada H., Arase Y., Chayama K., Saitoh S., Ikeda K., Kobayashi M., Suzuki Y., & Murashima N. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. European Journal of Gastroenterology & Hepatology 2002; 11: 1077–1083.
57. Iino S., Tango T., Matsushima T., Toda G., Miyake K., Hino K., Kumada H., Yasuda K., Kuroki T., Hirayama C., & Suzuki H. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatology Research 2001; 19: 31–40.
58. Miyake K., Tango T., Ota Y., Mitamura K., Yoshiba M., Kako M., Hayashi S., Ikeda Y., Hayashida N., Iwabuchi S., Sato Y., Tomi T., Funaki N., Hashimoto N., Umeda T., Miyazaki J., Tanaka K., Endo Y., & Suzuki H. Efficacy of Stronger Neominophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis. Journal of Gastroenterology & Hepatology 2002; 17: 1198–1204.
59. van Rossum T.G.J., Vulto A.G., Hop W.C.J., Brouwer J.T., Niesters H.G.M., & Schalm S.W. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled Phase I/II trial. Journal of Gastroenterology & Hepatology 1999; 14: 1093–1099.
60. van Rossum T.G.J., Vulto A.G., Hop W.C.J., & Schalm S.W. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. American Journal of Gastroenterology 2001; 96: 2432–2437.
61. Gotoh Y., Tada K., Yamada K., Minamitani M., Negishi M., Fujimaki M., Ikematsu S., Hada M., Mori K., Ito M., Shigeta S., Nakashima H., Yamamoto N., & Shiokawa Y. [Administration of glycyrrhizin to patients with human immunodeficiency virus infection]. Igaku no Ayumi 1987; 140: 619–620.
62. Mori K., Sakai H., Susuki S., Akutsu Y., Ishikawa M., Aihara M., Yokoyama M., Sato Y., Okaniwa S., & Endo Y. [The present status in prophylaxis and treatment of HIV infected patients with haemophilia in Japan]. Japanese Journal of Clinical Pathology 1989; 37: 1200–1208.
63. Barnes J., Anderson L.A., & Phillipson J.D. St John's wort (Hypericum perforatum L): a review of its chemistry, pharmacology and clinical properties. Journal of Pharmacy & Pharmacology 2001; 53: 583–600.
64. Gulick R.M., McAuliffe V., Holden-Wiltse J., Crumpacker C., Liebes L., Stein D.S., Meehan P., Hussey S., Forcht J., & Valentine F.T. Phase I studies of hypericin, the active compound of St. John's wort, as an antiretroviral agent in HIV-infected adults. Annals of Internal Medicine 1999; 130: 510–514.
65. Jacobson J.M., Feinman L., Liebes L., Ostrow N., Koslowski V., Tobia A., Cabana B.E., Lee D-H, Sprotzler J., & Prince A.M. Pharmacokinetics, safety and antiviral effects of hypericin, a derivative of St John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrobial Agents & Chemotherapy 2001; 45: 517–524.
66. Nakano M., Kurokawa M., Hozumi T., Saito A., Ida M., Morohashi M., Namba T., Kawana T., & Shiraki K. Suppression of recurrent genital herpes simplex virus type 2 infection by Rhus javanica in guinea pigs. Antiviral Research 1998; 39: 25–33.
67. Serkedjieva J., & Ivancheva S. Antiherpes virus activity of extracts from the medicinal plant Geranium sanguineum L. Journal of Ethnopharmacology 1999; 64: 59–68.
68. Kurokawa M., Basnet P., Ohsugi M., Hozumi T., Kadota S., Namba T., Kawana T., & Shiraki K. Anti-herpes simplex virus activity of moronic acid purified from Rhus javanica in vitro and in vivo. Journal of Pharmacology & Experimental Therapeutics 1999; 289: 72–78.
69. Nawawi A., Nakamura N., Hattori M., Kurokawa M., & Shiraki K. Inhibitory effects of Indonesian medicinal plants on the infection of herpes simplex virus type 1. Phytotherapy Research 1999; 13: 37–41.
70. Alche L.E., Berra A., Veloso M.J., & Coto C.E. Treatment with meliacine, a plant derived antiviral, prevents the developement of herpetic stromal keratitis in mice. Journal of Medical Virology 2000; 61: 474–480.
71. Nawawi A., Nakamura N., Meselhy M.R., Hattori M., Kurokawa M., Shiraki K., Kashiwaba N., & Ono M. In vivo antiviral activity of Stephania cepharantha against herpes simplex virus type-1. Phytotherapy Research 2001; 15: 497–500.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published: February 2003
Issue published: February 2003
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 903
*Article usage tracking started in December 2016
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 0
Crossref: 33
-
Anti-BVDV Activity of Traditional Chinese Medicine Monomers Targeting ...
-
Anti-Entry Activity of Natural Flavonoids against SARS-CoV-2 by Target...
-
Flavonoids as Potential Antiviral Agents for Porcine Viruses
-
West African medicinal plants and their constituent compounds as treat...
-
Antitussive noscapine and antiviral drug conjugates as arsenal against...
-
Plants with potent antiviral properties
-
Antiviral Potential of Selected Medicinal Herbs and Their Isolated Nat...
-
African and Asian Medicinal Plants as a Repository for Prospective Ant...
-
Antiviral activities of flavonoids
-
Quality Appraisal of the Pharmacoeconomic Research Literature about An...
-
The genus Cassia L.: Ethnopharmacological ...
-
Phytochemicals as potential drug candidates for targeting SARS CoV 2 p...
-
Biodiversity and Therapeutic Potential of Medicinal Plants
-
Anti-HIV lignans from Justicia procumbens
-
The anti‐hepatitis B virus therapeutic potential of anthraquinones der...
-
Diels-Alder adducts of 3-N-substituted derivatives of (−)-Cytisine as ...
-
Plant-derived antiviral drugs as novel hepatitis B virus inhibitors: C...
-
Anti-HIV Agents From Nature: Natural Compounds From Hypericum hircinum...
-
Medicinal plants: a repository of antiviral metabolites
-
In vitro antiplasmodial and HIV-1 neutralization activities of root an...
-
Evaluation of antirotavirus activity of flavonoids
-
Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for...
-
Traditional Indian medicine and homeopathy for HIV/AIDS: a review of t...
-
Differential effects of triptolide and tetrandrine on activation of CO...
-
Antiviral and immunomodulatory effect of a lyophilized extract of ...
-
Isolation of quinic acid derivatives and flavonoids from the aerial pa...
-
Herbal medicines as diuretics: A review of the scientific evidence
-
Special Feature
-
Antimicrobial Activity of the Medicinal Mushroom Ganoder...
-
Complementary and alternative medicine in the treatment of chronic liv...
-
Bioprospecting Rumphius's Ambonese Herbal: Volume I
-
Nelfinavir
-
Does complementary medicine have a role in infectious diseases?
Figures and tables
Figures & Media
Tables
View Options
View options
PDF/ePub
View PDF/ePubGet access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Alternatively, view purchase options below:
Access journal content via a DeepDyve subscription or find out more about this option.
